Earnings ·
Vir Biotechnology reports Q3 net loss of $0.57 per share and ends quarter with $901 million in cash
VIRVir Biotechnology, Inc.
Vir Biotechnology reported a third-quarter 2026 net loss of $96.3 million, or $0.57 per share, compared to a $163.1 million loss in the prior-year period. Research and development expenses decreased to $80.0 million from $151.5 million, primarily due to a non-recurring milestone expense in 2025 and cost recoveries from collaborations with Astellas and Norgine. The company ended the quarter with approximately $901 million in cash, cash equivalents, and investments, excluding $90 million received upfront from a Gilead collaboration. Pipeline updates include expected topline data for the pivotal ECLIPSE 1 trial in chronic hepatitis delta during Q4 2026, FDA Fast Track designation for VIR-5500 in prostate cancer, and plans to begin pivotal trials next year. Vir Biotechnology is a clinical-stage biopharmaceutical company focused on developing medicines for infectious diseases and cancer.